February 28, 2024

We are creating some awesome events for you. Kindly bear with us.

A*STAR’s advancements in medical technology

The Agency for Science, Technology and Research (A*STAR) has been a part of two medicinal discoveries in the treatment of cancer and eye diseases.

Green Tea based nanomedicines to treat cancer

An advanced nanocarrier for delivering anti-cancer drugs in the desired manner has been developed by researchers from A*STAR’s Institute of Bioengineering and Nanotechnology (IBN).

They created a compatible nanocarrier, which is derived from green tea catechins, for the anti-cancer drug for kidney cancer, Sunitinib (SU).

This greatly improved the performance of the anti-cancer drug during experiments for hindering the growth and spread of tumours, while significantly reducing the levels of toxicity which are typical of the treatment procedures.

The idea behind the design of these nanocarriers is a result of these two scenarios:

  1. Low-drug loading capacities

Nanocarriers usually have a low drug-loading capacity. This will result in the need for increasing the dosage or the rate of administering the drugs to meet the intended treatment results. The potential harms as a result of this are the rise in toxicity levels and other side effects.

  1. Elevating drug-loading runs

This will result in the instability of the nanocarrier and thus resulting in low efficiency and affect toxicity levels as well.

To avoid the above scenarios, the nanocarriers were developed with essential therapeutic properties, supplementing the anti-cancer drug’s efficiency and reducing the importance of the drug-to-carrier ratio.

Green tea contains an antioxidant known as epigallocatechin-3-O-gallate (EGCG) which can stop cancer when administered in large doses.

Back in 2014, IBN researchers developed self-assembling nanocarriers from EGCC and they have applied the same method in creating these advanced nanocarriers for delivering anti-cancer drugs.

The research team behind these nanocarriers is led by IBN Team Leader and Principal Research Scientist Dr Motoichi Kurisawa.

Dr Kurisawa said, “Our work has the potential to greatly alleviate the toxicity associated with normal regimens of the anti-cancer drug.”

He added that this latest creation of nanocarriers will allow for robust prevention of tumour growths while using lower dosages of the anti-cancer drug.

Potential new drug for treating vision loss

A collaboration between researchers from the University of Florida (UF) College of Pharmacy, the Singapore Eye Research Institute (SERI) and A*STAR’s Institute of Molecular and Cell Biology (IMCB) is looking at ways of finding a drug which can treat retinal diseases.

Eye diseases are commonly a result of abnormal blood vessel formations. Some of these diseases include neovascular age-related macular degeneration, neovascular glaucoma and advanced diabetic retinopathy.

Vascular endothelial growth factor (VEGF) is a protein which has been identified as a big contributor to abnormal blood vessel formation.

Thus, researchers are looking into whether Apratoxin S4, a new molecule which is based on marine cyanobacteria, is efficient in preventing the abnormal formation of blood vessels in the eye.

Apratoxin S4 is a member of a family of apratoxin molecules which can only be found in certain parts of the world’s oceans.

It was discovered during a laboratory testing that Apratoxin S4 prevents the formation of growth of abnormal blood vessels in the eye and does not affect regular blood vessels. The research proved the effectiveness of the drug as acting as a therapy of its own or together with other VEGF-inhibiting drugs which prevent abnormal growth of blood vessels.

Singapore’s population is highly vulnerable to eye diseases and disorders in every age group. The risk of blindness increases by fifteen times for Singaporeans aged 50 to 80 and above.

Professor Wanjin Hong, Ph.D., Executive Director of A*STAR’s IMCB, addressed the necessity for more options of eye disease treatments. He said that cases of eye disease will rise in the future, with vulnerability existing amongst every age group.

PARTNER

Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.

PARTNER

CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.

PARTNER

Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.

SUPPORTING ORGANISATION

SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.

PARTNER

HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 

PARTNER

IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.

Send this to a friend